Header Ads

Recovery and re-infection

Coronavirus Daily
Bloomberg

Here's the latest news:

Recovery and re-infection

There's a growing mystery over recovering Covid-19 patients who don't seem to get fully well. Some experience a re-activation of symptoms, or test positive again after earlier testing negative. Some are even potentially re-infected.

The issue is puzzling doctors and health experts, because it's not clear why symptoms seem to be coming back in some patients. It's also unknown if these patients continue to be infectious or if tests could be just picking up on dead virus particles.

Virus particles are shown emerging from the surface of cells cultured in the lab.

Photographer: BSIP/Universal Images Group Editorial

One thing is clear: these incidents are taking a major personal toll on patients who feel like they're on a roller-coaster with no certainty as to when they will be truly fine.

In reporting on this mystery, I've kept in touch with a handful of Covid-19 patients. Most are weeks into the disease and thought they were over the worst of it, but remain puzzled and scared by lingering symptoms like breathlessness, body aches and stomach issues that would come and go. As the days passed, some would report happily to me that they were feeling better, while others would send updates full of frustration as they reported chest pains or shortness of breath, some of which resulted in an emergency room visit.

This mystery will also impact major issues like the development of a vaccine and how quickly governments can lift their lockdowns. If not all survivors develop real immunity to the virus, everything is thrown into uncertainty. In the long run, health-care systems, social safety nets and insurers could come under added strain.

The official statistics show that just over 1 million people and growing have officially recovered from the coronavirus. But for some like those I've interviewed, recovery is anything but simple.—Lisa Du

Treating the virus

Latest Podcast: Danger in Superfast Science

Science doesn't usually move this fast. Michelle Fay Cortez and Robert Langreth show what happens when the slow and steady process of research, peer review, and the publication process hits warp speed.

The Most Promising Drugs and Vaccines

Gilead Sciences' antiviral drug remdesivir cleared by U.S. regulators for emergency use in Covid-19 patients, and all the latest updates on the race for a treatment.

What you should read

Hawaii Travel Paradise Is Deserted 
Business is down 95% for some locals who rely on tourism.
Covid Exit Depends on Vaccine Production
Competing global interests snarl vaccine supply priorities.
The Fed Saved Boeing Without Paying a Dime
Less than 2 months ago Boeing asked for $60 billion. Now, it's good.
This Tiny Widget Exposes Supply-Chain Risk

It was one of the smallest pieces in the world's biggest science project
U.S. Beef Output Down Far More Than Estimated
Slaughter rates are sinking.

Know someone else who would like this newsletter?  Have them sign up here.

Have any questions, concerns, or news tips on Covid-19 news? Get in touch or help us cover the story.

Like this newsletter? Subscribe for unlimited access to trusted, data-based journalism in 120 countries around the world and gain expert analysis from exclusive daily newsletters, The Bloomberg Open and The Bloomberg Close.

No comments